The latest long-term debt for KDNY is $30M as of June 2023. That compares with $37M in the prior-year period — down 20.0% year over year. Investors often review this figure alongside Chinook Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, KDNY's long-term debt moved from $37M to $30M — a 20.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Chinook Therapeutics's operating scale or balance-sheet position.

A long-term debt figure of $30M for KDNY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting KDNY's long-term debt ($30M), review year-over-year change from $37M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Chinook Therapeutics's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.